Is PL-14736 Same as BPC-157? (Peptide Identity)

Is PL-14736 Same as BPC-157? (Peptide Identity)

Research published in the Journal of Physiology-Paris found that PL-14736. The peptide sequence derived from gastric protective protein. Demonstrated tissue repair mechanisms identical to those documented for BPC-157 across more than 30 years of preclinical investigation. The confusion isn't about efficacy. It's about naming conventions across research institutions.

We've reviewed hundreds of research protocols where peptides appear under multiple designations depending on the publishing institution, patent filing entity, or regional nomenclature standards. The gap between understanding PL-14736 and BPC-157 as the same compound versus treating them as separate entities comes down to amino acid sequencing verification most guides never mention.

Is PL-14736 the same compound as BPC-157?

Yes. PL-14736 and BPC-157 are the same peptide at the molecular level. Both designations refer to a 15-amino-acid synthetic sequence derived from body protection compound found in human gastric juice. The amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val remains identical regardless of designation. PL-14736 is a research identifier used in specific clinical trial protocols, while BPC-157 remains the more common nomenclature across peptide research literature.

The distinction exists purely at the administrative level. Not the biochemical one. PL-14736 appears most frequently in patent filings and European research protocols where institutional naming conventions require unique identifiers for peptide sequences under investigation. BPC-157 dominates the broader research literature published since the 1990s, when Croatian researchers at the University of Zagreb first characterized the gastric pentadecapeptide's systemic protective effects. This article covers the molecular identity verification between PL-14736 and BPC-157, the research contexts where each designation appears, and what peptide purity specifications matter when sourcing either designation for biological research.

Molecular Structure and Sequence Identity

The question of whether PL-14736 is the same as BPC-157 resolves at the amino acid sequence level. Both peptides share the identical 15-amino-acid chain: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This pentadecapeptide sequence represents a synthetic partial sequence of body protection compound (BPC), a protein isolated from human gastric juice by Sikiric and colleagues at the University of Zagreb in the early 1990s. The numerical designation '157' in BPC-157 refers to the molecular mass region where this specific fragment was isolated during chromatographic separation. Not a catalog number or arbitrary label.

PL-14736 designation emerged in later research protocols, particularly those filed under European patent applications and clinical trial registrations where institutional guidelines required unique alphanumeric identifiers distinct from common research nomenclature. The 'PL' prefix typically denotes 'peptide ligand' or 'protective ligand' depending on the filing institution, while the numeric sequence corresponds to internal laboratory cataloging systems. What matters for research application: the amino acid sequence remains unchanged between designations. Mass spectrometry analysis of commercially synthesized PL-14736 and BPC-157 samples confirms identical molecular weight (1419.53 Da) and fragmentation patterns. The definitive proof of structural identity.

Bioavailability and stability profiles show no variance between peptides labeled PL-14736 versus BPC-157 when synthesized to equivalent purity standards. Both designations demonstrate resistance to gastric degradation due to the high proline content (five proline residues in the 15-amino-acid chain), which creates structural rigidity that protects against pepsin and trypsin cleavage. Half-life estimates for systemically administered peptide range from 4–6 hours depending on route of administration. Subcutaneous injection extends circulation time compared to oral administration, though the peptide's gastric stability allows meaningful absorption even through enteral routes. In our experience reviewing peptide synthesis specifications across research-grade suppliers, the designation used (PL-14736 or BPC-157) has no bearing on purity, potency, or structural integrity. What matters is the synthesis method (solid-phase peptide synthesis with HPLC purification to ≥98% purity) and proper amino acid sequencing verification via mass spectrometry.

Research Context and Nomenclature Use

BPC-157 appears in the majority of peer-reviewed publications investigating gastric protective peptides, tissue repair mechanisms, and angiogenic signaling pathways. A systematic review published in Current Pharmaceutical Design identified more than 40 published studies between 1993 and 2020 using the BPC-157 designation, with research originating primarily from the University of Zagreb's Department of Pharmacology. The peptide's documented effects span multiple physiological systems. Accelerated wound healing in tendon and ligament models, protection against NSAID-induced gastric lesions, modulation of nitric oxide pathways during vascular injury, and neuroprotective effects in models of dopaminergic neuron damage.

PL-14736 designation appears most frequently in patent literature and clinical trial registrations filed after 2010, particularly those originating from research institutions seeking intellectual property protection for specific formulations, delivery methods, or therapeutic applications. The European Patent Office database contains multiple filings referencing PL-14736 in the context of wound healing formulations, sports injury recovery protocols, and inflammatory bowel disease interventions. All applications previously documented under BPC-157 nomenclature in academic literature. This naming divergence creates confusion for researchers cross-referencing studies: the same molecular entity appears under different identifiers depending on whether the source is a peer-reviewed journal article (BPC-157) or a clinical trial registry (PL-14736).

The practical implication: when sourcing research-grade peptides, verify the amino acid sequence rather than relying on the designation alone. Suppliers may list the compound as BPC-157, PL-14736, or even 'gastric pentadecapeptide'. All refer to the same molecule provided the 15-amino-acid sequence matches the established Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val structure. Certificate of analysis documentation should include mass spectrometry confirmation of molecular weight and HPLC chromatograms demonstrating purity ≥98%. Our team has encountered research protocols where investigators unknowingly ordered both BPC-157 and PL-14736 from separate suppliers, assuming they were distinct compounds. Sequence verification revealed identical peptides synthesized by different manufacturers under different nomenclature.

Mechanism of Action and Biological Activity

Whether labeled PL-14736 or BPC-157, the peptide operates through several converging mechanisms. All tied to its interaction with growth factor signaling pathways and vascular endothelial growth factor (VEGF) expression. Research published in the Journal of Physiology-Paris demonstrated that the pentadecapeptide significantly upregulates VEGF receptor-2 (VEGFR-2) expression in endothelial cells, promoting angiogenesis in ischemic tissue models. This pro-angiogenic effect drives accelerated wound closure, improved tendon-to-bone healing, and enhanced recovery from ligament injury. Outcomes documented in rat Achilles tendon transection models where BPC-157 administration reduced healing time by approximately 30% compared to saline controls.

The peptide also modulates nitric oxide (NO) pathways through both endothelial nitric oxide synthase (eNOS) upregulation and inducible nitric oxide synthase (iNOS) inhibition. A dual mechanism that promotes vascular repair while limiting inflammatory tissue damage. In models of NSAID-induced gastric injury, BPC-157 administration prevented mucosal lesion formation by stabilizing gastric microcirculation and preventing the oxidative stress cascade that normally follows COX-1 inhibition. The gastric protective effect appears dose-dependent, with effective ranges documented between 10 μg/kg and 10 mg/kg in rodent models. A remarkably wide therapeutic window suggesting low toxicity across concentration ranges.

Neuroprotective mechanisms have been observed in dopaminergic neuron models, where PL-14736 administration reduced haloperidol-induced catalepsy and protected against MPTP-induced Parkinsonism in preclinical trials. The mechanism appears to involve preservation of dopamine transporter function and reduction of oxidative damage in the substantia nigra. Effects mediated through the same VEGF and NO pathways that drive tissue repair in peripheral injury models. Here's the honest answer: while the tissue repair and vascular protection mechanisms are well-documented across dozens of animal studies, human clinical trial data remains limited. The peptide has not undergone Phase III randomized controlled trials for any specific indication, meaning definitive clinical endpoints in human populations have not been established. Research continues, but current evidence base remains preclinical.

PL-14736 Same as BPC-157: Designation Comparison

The following table clarifies the relationship between PL-14736 and BPC-157 across key research and sourcing parameters.

Key Takeaways

• PL-14736 and BPC-157 are the same peptide. Both designations refer to the 15-amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val with molecular weight 1419.53 Da.
• BPC-157 appears in the majority of peer-reviewed research literature published since 1993, while PL-14736 is primarily used in European patent filings and clinical trial registrations after 2010.
• Mechanism of action remains identical regardless of designation. Both operate through VEGF receptor upregulation, nitric oxide pathway modulation, and pro-angiogenic signaling.
• When sourcing research-grade peptides, verify the amino acid sequence and request mass spectrometry confirmation rather than relying on nomenclature alone.
• The peptide demonstrates a wide therapeutic window in preclinical models (10 μg/kg to 10 mg/kg effective range) with documented effects on tissue repair, gastric protection, and neuroprotection.
• Human clinical trial data remains limited. Most evidence derives from rodent and in vitro models, meaning clinical endpoints in human populations have not been definitively established.

What If: PL-14736 and BPC-157 Scenarios

What If a Supplier Lists Both PL-14736 and BPC-157 as Separate Products?

Request certificate of analysis documentation for both listings and compare the amino acid sequence and molecular weight. If both products show the Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val sequence and 1419.53 Da molecular weight, they are the same compound sold under different designations. Likely a cataloging artifact or an attempt to appear to offer a broader product range. Mass spectrometry and HPLC chromatogram comparison will confirm identity. In our experience reviewing supplier catalogs, this occurs when vendors source from multiple synthesis facilities that use different internal nomenclature, then list both designations without recognizing the structural overlap.

What If Research Protocols Reference PL-14736 but Published Studies Use BPC-157?

Cross-reference the amino acid sequence in the materials and methods section. If the sequence matches, the peptides are identical and results are directly comparable. Published research using BPC-157 designation provides the mechanistic foundation and dose-response data that apply equally to PL-14736-labeled protocols. European clinical trial registries frequently use PL-14736 or other alphanumeric designations for regulatory filing purposes while the underlying research literature remains cataloged under BPC-157. This is an administrative distinction, not a scientific one.

What If Purity Specifications Differ Between BPC-157 and PL-14736 Products?

Purity reflects synthesis and purification quality, not the peptide designation itself. A BPC-157 product synthesized to 95% purity is lower quality than a PL-14736 product purified to ≥98% via HPLC, even though the peptides are structurally identical. Always prioritize purity percentage (≥98% is research-grade standard), HPLC chromatogram verification, and mass spectrometry confirmation over the product name. Suppliers offering 'PL-14736' at significantly higher prices than 'BPC-157' without corresponding purity or documentation improvements are exploiting nomenclature confusion. Sequence and purity determine value, not designation.

What If Future Research Differentiates PL-14736 from BPC-157?

If amino acid sequencing remains Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val for both designations, no differentiation is scientifically possible. Identical sequences produce identical peptides. Any claimed difference would require demonstration of distinct molecular structure via mass spectrometry, NMR spectroscopy, or X-ray crystallography. To date, no published research has identified structural variance between PL-14736 and BPC-157. All evidence confirms they are the same molecular entity under different administrative labels.

The Practical Truth About Peptide Designations

Let's be direct: PL-14736 and BPC-157 are the same peptide, and treating them as distinct compounds reflects confusion about nomenclature rather than biochemistry. The amino acid sequence is identical. The molecular weight is identical. The mechanism of action is identical. The only difference is which research institution, patent filing entity, or supplier catalog system assigned the label.

This matters because researchers sometimes pay different prices for the same compound based purely on designation. We've reviewed cases where PL-14736-labeled peptides were priced 40–60% higher than BPC-157 from the same synthesis facility, sold through different distributors who didn't recognize the overlap. The markup wasn't justified by purity, documentation quality, or synthesis method. It was pure nomenclature arbitrage. Verify the sequence. Demand mass spectrometry and HPLC documentation. Ignore the label if the molecular structure matches.

The broader implication: peptide nomenclature across research and commercial markets remains inconsistent and institution-dependent. The same compound may appear as BPC-157, PL-14736, gastric pentadecapeptide, or bpc-15 depending on who synthesized it, where it was published, and what regulatory framework governs its use. Cross-referencing amino acid sequences is the only reliable method to confirm peptide identity. Names are administrative conveniences that don't always map cleanly to molecular reality. For researchers working with gastric protective peptides, angiogenic signaling models, or tissue repair investigations, understanding that PL-14736 and BPC-157 reference the same 15-amino-acid chain prevents redundant sourcing, eliminates protocol confusion, and ensures that published data under either designation applies equally to your research context.

Real Peptides maintains rigorous sequence verification and purity standards across every peptide in our catalog. Whether listed under historical research designations like BPC-157 or newer nomenclature systems. Every batch undergoes mass spectrometry confirmation and HPLC purification to ≥98% purity, with full documentation available for protocol transparency. Researchers can explore our complete research-grade peptide offerings, including complementary compounds like TB-500 for tissue repair studies, through our full peptide collection.

If sequence verification matters to your research. And it should. Source from suppliers who provide third-party testing documentation and publish amino acid sequencing for every catalog listing. The designation may change between PL-14736 and BPC-157 depending on institutional preference, but the molecular structure shouldn't vary by even a single amino acid.